Abstract:Objective: This study aimed to identify the most common and top drugs associated with the risk of torsades de pointes (TdP) based on the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Materials and methods: We used OpenVigil 2.1 to query FAERS database and data from the first quarter of 2004 to the third quarter of 2021 were retrieved. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify TdP cases. We listed the most common drugs associated with the reported TdP cases. Then, the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) for the reporting association between different drugs and TdP risk were calculated. Meanwhile, comparisons were conducted with the QT drug lists of CredibleMeds ® in an attempt to identify drugs with a potential risk of TdP that were not on the list. Results: A total of 9,217,181 adverse event reports were identified, of which 3,807 (0.04%) were related to TdP. TdP was more likely to occur in the elderly and females. Amiodarone (464 cases) was associated with most cases of TdP. According to the disproportionality analysis, the top five drugs with the highest ROR and PRR were tolazoline (ROR 1615.11, 95% confidence interval [CI] 455.59–5725.75, PRR 969.46, χ 2 2960.10), levomethadyl (ROR 1211.01, 95% CI 302.75–4844.04, PRR 807.67, χ 2 1677.03), ibutilide (ROR 1118.74, 95% CI 425.00–2944.91, PRR 765.77, χ 2 3845.27), halofantrine (ROR 660.55, 95% CI 184.21–2368.69, PRR 519.22, χ 2 1076.31), and isoproterenol (ROR 352.20, 95% CI 227.19–546.00, PRR 307.82, χ 2 6692.53). Approximately half of the top 50 drugs (22 for ROR, 30 for PRR) were not outlined on the QT drug lists of CredibleMeds ® . Conclusion: Approximately half of the top risk drugs (22 for ROR, 30 for PRR) were not outlined in the QT drug lists of CredibleMeds ® . Notably, potential risks are of great importance and should be closely monitored in clinical practice. Also, further research is needed to investigate the association between these drugs and TdP.

Prevention of Torsade de Pointes in Hospital Settings

Diagnosis and Treatment of Drug Induced Acquired Long QT Syndrome

Drug-induced QT interval prolongation and torsades de pointes

Torsade de pointes in a patient with complete atrioventricular block and pacemaker failure, misdiagnosed with epilepsy.

Fluoroquinolone-induced torsade de pointes

Dobutamine Infusion for Unmasking Long QT Syndrome and Torsades De Pointes.

[Clinical Practice Guidelines for Long Q-T Interval Syndrome].

Repolarization Injury and Occurrence of Torsades de Pointes During Acute Takotsubo Syndrome

Mechanisms of torsades de pointes: an update

Mechanisms underlying arrhythmogenesis in long QT syndrome

Long QT Syndrome With Drugs Used in the Management of Arrhythmias: A Systematic Review

An Updated Safety Review of the Relationship Between Atypical Antipsychotic Drugs, the QTc Interval and Torsades de Pointe As: Implications for Clinical Use

Drug-induced proarrhythmia: Discussion and considerations for clinical practice

Roles of Atrial Arrhythmias in Triggering Torsade de Pointes in Patients With Acquired Long-QT Syndrome

Incidence and clinical characteristics of patients with torsades de pointes complicating acquired atrioventricular block

Mechanisms underlying spontaneous termination of Torsade de Pointes in an experimental model of long QT syndrome

Class III Antiarrhythmics and Periprocedural Torsades de Pointes

Early Afterdepolarizations in the Familial Long Qtu Syndrome

Torsade de pointes caused by citalopram during the pacemaker battery-depletion phase: A case report

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system

QT Prolongation Preceding Ventricular Fibrillation After Amiodarone Administration: A Case Report